Facetten
Zugriff
Einrichtung
Medientyp
- Text 10
Karte
Erscheinungsjahr
Autor/in
- Ettl, Johannes
- Fasching, Peter A
- Hartkopf, Andreas D 7
- Lüftner, Diana 7
- Müller, Volkmar 6
- alle zeigen
Sprache
- Englisch 10
10 Einträge gefunden
-
Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients - Data from the Real-World Registry PRAEGNANT
- Engler, Tobias
- Fasching, Peter A
- Lüftner, Diana
- Hartkopf, Andreas D
- Müller, Volkmar
- Kolberg, Hans-Christian
- Hadji, Peyman
-
Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registry
- Müller, Volkmar
- Hein, Alexander
- Hartkopf, Andreas D
- Fasching, Peter A
- Kolberg, Hans-Christian
- Hadji, Peyman
- Tesch, Hans
-
Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany"
- Schneeweiss, Andreas
- Ettl, Johannes
- Lüftner, Diana
- Beckmann, Matthias W
- Belleville, Erik
- Fasching, Peter A
- Fehm, Tanja N
-
-
Update Breast Cancer 2020 Part 3 - Early Breast Cancer
- Huober, Jens
- Schneeweiss, Andreas
- Hartkopf, Andreas D
- Müller, Volkmar
- Lux, Michael P
- Janni, Wolfgang
- Ettl, Johannes
-
Update Breast Cancer 2020 Part 4 - Advanced Breast Cancer
- Tesch, Hans
- Müller, Volkmar
- Wöckel, Achim
- Ettl, Johannes
- Belleville, Erik
- Schütz, Florian
- Hartkopf, Andreas
-
Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
- Michel, Laura L
- Hartkopf, Andreas D
- Fasching, Peter A
- Kolberg, Hans-Christian
- Hadji, Peyman
- Tesch, Hans
- Häberle, Lothar
-
Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany
- Schneeweiss, Andreas
- Ettl, Johannes
- Lüftner, Diana
- Beckmann, Matthias W
- Belleville, Erik
- Fasching, Peter A
- Fehm, Tanja N
-
ABC5 International Consensus Conference on Advanced Breast Cancer, Lisbon, 16 November 2019:Commentary by the German panel of experts on the ABC5 voting results
- Untch, Michael
- Würstlein, Rachel
- Lüftner, Diana
- Haidinger, Renate
- Fasching, Peter A
- Augustin, Doris
- Briest, Susanne
-